Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: A pilot study

Pituitary

Volumn 17, Issue 2, 2014, Pages 150-156

  Barake, Maya ^a,b   Evins, A Eden ^a,b   Stoeckel, Luke ^a,b   Pachas, Gladys N ^a,b   Nachtigall, Lisa B ^a,b   Miller, Karen K ^a,b   Biller, Beverly M K ^a,b   Tritos, Nicholas A ^a,b   Klibanski, Anne ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cabergoline; Dopamine agonist; Hyperprolactinemia; Impulsivity; Pituitary adenoma

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AGED; ARTICLE; BARRATT IMPULSIVENESS SCALE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS DISEASE; IMPULSIVENESS; MALE; PILOT STUDY; PRIORITY JOURNAL; PSYCHOMETRY; QUESTIONNAIRE; SELF REPORT; TERTIARY HEALTH CARE; TREATMENT OUTCOME;

ADULT; AGED; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; HYPERPROLACTINEMIA; IMPULSIVE BEHAVIOR; MALE; MIDDLE AGED; PILOT PROJECTS; PREVALENCE; PSYCHOMETRICS; QUESTIONNAIRES; SELF REPORT; TREATMENT OUTCOME;

EID: 84898809300     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-013-0480-6     Document Type: Article

References (21)

1. Klibanski A (2010) Clinical practice. Prolactinomas N Engl J Med 362(13):1219-1226
2. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65(2):265-273
3. Dang D, Cunnington D, Swieca J (2011) The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome. Clin Neuropharmacol 34(2):66-70
4. Voon V, Reynolds B, Brezing C, Gallea C, Skaljic M, Ekanayake V, Fernandez H, Potenza MN, Dolan RJ, Hallett M (2010) Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology 207(4):645-659
5. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67(5):589-595
6. Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC (2001) Psychiatric aspects of impulsivity. Am J Psychiatry 158(11):1783-1793
7. Martinkova J, Trejbalova L, Sasikova M, Benetin J, Valkovic P (2011) Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin Neuropharmacol 34(5):179-181
8. Falhammar H, Yarker JY (2009) Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Aust 190(2):97
9. Davie M (2007) Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. J Neuropsychiatry Clin Neurosci 19(4):473-474
10. Campbell-Sills L, Liverant GI, Brown TA (2004) Psychometric evaluation of the behavioral inhibition/behavioral activation scales in a large sample of outpatients with anxiety and mood disorders. Psychol Assess 16(3):244-254
11. Meyer B, Johnson SL, Carver CS (1999) Exploring behavioral activation and inhibition sensitivities among college students at risk for bipolar spectrum symptomatology. J Psychopathol Behav Assess 21(4):275-292
12. Patton JH, Stanford MS, Barratt ES (1995) Factor structure of the Barratt impulsiveness scale. J Clin Psychol 51(6):768-774
13. Lejuez CW, Read JP, Kahler CW, Richards JB, Ramsey SE, Stuart GL, Strong DR, Brown RA (2002) Evaluation of a behavioral measure of risk taking: the balloon analogue risk task (BART). J Exp Psychol Appl 8(2):75-84
14. Reynolds B, Schiffbauer R (2004) Measuring state changes in human delay discounting: an experiential discounting task. Behav Process 67(3):343-356
15. Meda SA, Stevens MC, Potenza MN, Pittman B, Gueorguieva R, Andrews MM, Thomas AD, Muska C, Hylton JL, Pearlson GD (2009) Investigating the behavioral and self-report constructs of impulsivity domains using principal component analysis. Behav Pharmacol 20(5-6):390-399
16. Dalley JW, Roiser JP (2012) Dopamine, serotonin and impulsivity. Neuroscience 215:42-58
17. Rokosik SL, Napier TC (2012) Pramipexole-induced increased probabilistic discounting: comparison between a rodent model of Parkinson's disease and controls. Neuropsychopharmacology 37(6):1397-1408
18. Voon V, Mehta AR, Hallett M (2011) Impulse control disorders in Parkinson's disease: recent advances. Curr Opin Neurol 24(4):324-330
19. Harris YT, Harris AZ, Deasis JM, Ferrando SJ, Reddy N, Young RC (2012) Cabergoline associated with first episode mania. Psychosomatics 53:595-600
20. Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, Moberg PJ, Stern MB (2006) Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63(7):969-973
21. Hassan A, Bower JH, Kumar N, Matsumoto JY, Fealey RD, Josephs KA, Ahlskog JE (2011) Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat Disord 17(4):260-264